Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
出版年份 2017 全文链接
标题
Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2017-11-13
DOI
10.3389/fimmu.2017.01544
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen–Containing Particles
- (2017) María López-Montañés et al. JOURNAL OF IMMUNOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer
- (2017) Jing Sun et al. Oncology Letters
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation
- (2017) Miguel López-Botet et al. Frontiers in Immunology
- HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
- (2017) Amy K. Erbe et al. Frontiers in Immunology
- Type I Interferons and Natural Killer Cell Regulation in Cancer
- (2017) Lena Müller et al. Frontiers in Immunology
- Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
- (2017) Patrick G. Gavin et al. JAMA Oncology
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8 + T Cells
- (2016) Deepak Mittal et al. CANCER RESEARCH
- PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors
- (2016) Roxanne Charlebois et al. CANCER RESEARCH
- Improved Survival of HER2+Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain
- (2016) Keith L. Knutson et al. CANCER RESEARCH
- Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer
- (2016) V. Varadan et al. CLINICAL CANCER RESEARCH
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
- (2016) S. J. Blake et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma
- (2016) M. Carlsten et al. CLINICAL CANCER RESEARCH
- Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I
- (2016) Jeanette E. Boudreau et al. IMMUNITY
- Adaptive NKG2C+NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients
- (2016) Dolores Redondo-Pachón et al. JOURNAL OF IMMUNOLOGY
- CIS is a potent checkpoint in NK cell–mediated tumor immunity
- (2016) Rebecca B Delconte et al. NATURE IMMUNOLOGY
- Targeting natural killer cells in cancer immunotherapy
- (2016) Camille Guillerey et al. NATURE IMMUNOLOGY
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion
- (2016) D. Gotthardt et al. Cancer Discovery
- IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
- (2016) Anja K. Wege et al. Oncotarget
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas
- (2016) Peter S. Kim et al. Oncotarget
- Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
- (2016) Joerg U. Schmohl et al. Oncotarget
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
- (2016) Claudia Cantoni et al. Journal of Immunology Research
- KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors
- (2016) Cristina Morales-Estevez et al. Frontiers in Immunology
- Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer
- (2016) Zhenyu Xu et al. OncoImmunology
- Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab
- (2015) Hee Jin Lee et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
- (2015) Eric F. Zhu et al. CANCER CELL
- Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
- (2015) David J. DiLillo et al. CELL
- Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
- (2015) M. Callari et al. CLINICAL CANCER RESEARCH
- Newtonian cell interactions shape natural killer cell education
- (2015) Jodie P. Goodridge et al. IMMUNOLOGICAL REVIEWS
- Human KIR repertoires: shaped by genetic diversity and evolution
- (2015) Angela R. Manser et al. IMMUNOLOGICAL REVIEWS
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation
- (2015) Manuela Moraru et al. JOURNAL OF IMMUNOLOGY
- Antibody-Mediated Response of NKG2CbrightNK Cells against Human Cytomegalovirus
- (2015) Marcel Costa-Garcia et al. JOURNAL OF IMMUNOLOGY
- Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
- (2015) Simone Battella et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
- (2015) E Muraro et al. Journal of Translational Medicine
- CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
- (2015) F Cichocki et al. LEUKEMIA
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS
- (2015) Miguel F. Sanmamed et al. SEMINARS IN ONCOLOGY
- Adaptive Immune Resistance: How Cancer Protects from Immune Attack
- (2015) A. Ribas Cancer Discovery
- Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition
- (2015) Martina Di Modica et al. Oncotarget
- Prognostic and predictive value of PDL1 expression in breast cancer
- (2015) Renaud Sabatier et al. Oncotarget
- Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions
- (2015) D. J. DiLillo et al. Cancer Immunology Research
- The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy
- (2015) T. A. Waldmann Cancer Immunology Research
- NKG2D Ligands in Tumor Immunity: Two Sides of a Coin
- (2015) Jinyu Zhang et al. Frontiers in Immunology
- Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment
- (2015) Monica Parodi et al. OncoImmunology
- Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion
- (2015) Bharat K. R. Chaganty et al. OncoImmunology
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
- (2015) Jonathan Pol et al. OncoImmunology
- Progressive loss of anti-HER2 CD4+T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
- (2015) Jashodeep Datta et al. OncoImmunology
- ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer
- (2015) Katharina Feldinger et al. Oncotarget
- ADAM10 and ADAM17: New Players in Trastuzumab Resistance
- (2015) Michael J. Duffy et al. Oncotarget
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- (2014) Witold Lasek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30
- (2014) E. Schlecker et al. CANCER RESEARCH
- Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
- (2014) B. Wang et al. CANCER RESEARCH
- Effect of tumor cells and tumor microenvironment on NK-cell function
- (2014) Massimo Vitale et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
- (2014) N. Korde et al. HAEMATOLOGICA
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Human NK cell response to pathogens
- (2014) Mariella Della Chiesa et al. SEMINARS IN IMMUNOLOGY
- HMGB1-Promoted and TLR2/4-Dependent NK Cell Maturation and Activation Take Part in Rotavirus-Induced Murine Biliary Atresia
- (2014) Yinrong Qiu et al. PLoS Pathogens
- Association Studies of Fc Receptor Polymorphisms with Outcome in HER2+ Breast Cancer Patients Treated with Trastuzumab in NCCTG (Alliance) Trial N9831
- (2014) N. Norton et al. Cancer Immunology Research
- The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells
- (2014) Cristina Cerboni et al. Frontiers in Immunology
- Classification of human natural killer cells based on migration behavior and cytotoxic response
- (2013) B. Vanherberghen et al. BLOOD
- NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
- (2013) R. Romee et al. BLOOD
- NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
- (2013) V. Beziat et al. BLOOD
- Cancer Immunosurveillance and Immunoediting by Natural Killer Cells
- (2013) Emilie Gross et al. CANCER JOURNAL
- Molecular determinants of trastuzumab efficacy: What is their clinical relevance?
- (2013) Pradip De et al. CANCER TREATMENT REVIEWS
- Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
- (2013) R. M. Srivastava et al. CLINICAL CANCER RESEARCH
- NKG2Czygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus
- (2013) Aura Muntasell et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Peripheral Blood NK Cells from Breast Cancer Patients Are Tumor-Induced Composite Subsets
- (2013) E. Mamessier et al. JOURNAL OF IMMUNOLOGY
- Activating natural cytotoxicity receptors of natural killer cells in cancer and infection
- (2013) Joachim Koch et al. TRENDS IN IMMUNOLOGY
- Analysis of Fc Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients
- (2012) S. A. Hurvitz et al. CLINICAL CANCER RESEARCH
- Combination strategies to enhance antitumor ADCC
- (2012) Holbrook E Kohrt et al. Immunotherapy
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer
- (2012) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer immunoediting by the innate immune system in the absence of adaptive immunity
- (2012) Timothy O’Sullivan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines
- (2012) R. Okita et al. JOURNAL OF IMMUNOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
- (2012) Aron M. Levin et al. NATURE
- Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response
- (2012) Barbara Morandi et al. PLoS One
- Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death
- (2012) Jamie A. Lopez et al. TRENDS IN IMMUNOLOGY
- Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression
- (2012) Masayuki Inoue et al. OncoImmunology
- Human Breast Tumor Cells Induce Self-Tolerance Mechanisms to Avoid NKG2D-Mediated and DNAM-Mediated NK Cell Recognition
- (2011) E. Mamessier et al. CANCER RESEARCH
- Pertuzumab in Combination with Trastuzumab Shows Significantly Enhanced Antitumor Activity in HER2-Positive Human Gastric Cancer Xenograft Models
- (2011) Y. Yamashita-Kashima et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity
- (2011) Emilie Mamessier et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- Production
- (2011) A. C. Jaime-Ramirez et al. JOURNAL OF IMMUNOLOGY
- Helper Activity of Natural Killer Cells During the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells
- (2011) Jeffrey L. Wong et al. JOURNAL OF IMMUNOTHERAPY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells
- (2010) H. Lu et al. CLINICAL CANCER RESEARCH
- E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells
- (2010) Chisako Yamauchi et al. INTERNATIONAL JOURNAL OF CANCER
- HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients
- (2010) E. M. de Kruijf et al. JOURNAL OF IMMUNOLOGY
- Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer
- (2010) Rohit Bhargava et al. MODERN PATHOLOGY
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Resistance to Trastuzumab in Breast Cancer
- (2009) P. R. Pohlmann et al. CLINICAL CANCER RESEARCH
- The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans
- (2009) Cameron S. Brandt et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
- (2009) T. S. Bekaii-Saab et al. MOLECULAR CANCER THERAPEUTICS
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
- (2008) W. Lin et al. BLOOD
- A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
- (2008) Aruna Mani et al. BREAST CANCER RESEARCH AND TREATMENT
- HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
- (2008) Simona Vertuani et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Tumor-Associated MICA Is Shed by ADAM Proteases
- (2008) I. Waldhauer et al. CANCER RESEARCH
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Correlation between NK function and response to trastuzumab in metastatic breast cancer patients
- (2008) Alessandra Beano et al. Journal of Translational Medicine
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- Stromal gene expression predicts clinical outcome in breast cancer
- (2008) Greg Finak et al. NATURE MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started